ALFRED GELLHORN, M.D.; VINCENT P. COLLINS, M.D.
This content is PDF only. Please click on the PDF icon to access.
The nitrogen mustard, methyl bis (beta chloroethyl) amine (HN2), was introduced as a chemotherapeutic agent in the treatment of malignant disease in 1943 by Goodman et al.1 Since that time there have been over 50 reports in the American literature describing the immediate effects of nitrogen mustard on a variety of neoplastic processes. Although there has been excellent agreement on the qualitative responses observed in the various clinics, there is but one report which assesses quantitatively the contribution of HN2 in the medical management of certain malignant diseases.2 Since HN2 is now commercially available to the medical profession under the
GELLHORN A, COLLINS VP. A QUANTITATIVE EVALUATION OF THE CONTRIBUTION OF NITROGEN MUSTARD TO THE THERAPEUTIC MANAGEMENT OF HODGKIN'S DISEASE*. Ann Intern Med. 1951;35:1250–1259. doi: https://doi.org/10.7326/0003-4819-35-6-1250
Download citation file:
Published: Ann Intern Med. 1951;35(6):1250-1259.
Results provided by:
Copyright © 2020 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use